Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedVantx Automates OTC Drug Sampling At Point Of Care

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble'sPrilosec OTC will be one of the first nonprescription drugs to be offered through automated "Sample Centers"- ATM-like dispensers placed in physicians' offices - as part of the MedVantx OTC Advantage program

You may also be interested in...



Industry News Roundup

Nexium 24HR Sample Pack Approved; Boots Protection Claims Imply Prevention; Support of Philosophy serum is “inherently arbitrary,” NAD said; Nestle Formula Comparative Claims Apply Across Entire Category; Happy consumers OK for U.K. e-cig ads; Manzo Scouts Probiotic Path At FDA and Ingredion acquires Penford.

Industry News Roundup

Nexium 24HR Sample Pack Approved; Boots Protection Claims Imply Prevention; Support of Philosophy serum is “inherently arbitrary,” NAD said; Nestle Formula Comparative Claims Apply Across Entire Category; Happy consumers OK for U.K. e-cig ads; Manzo Scouts Probiotic Path At FDA and Ingredion acquires Penford.

Clarinex Clinical, Safety Characteristics Support OTC Use – WellPoint

The similar safety and efficacy profile of Schering-Plough's follow-on drug Clarinex (desloratadine) to other second-generation antihistamines makes it appropriate for OTC availability, WellPoint Health Networks asserts in an April 15 petition to FDA

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel